Structural Heart Devices Market: Innovation, M&A, and Market Share

Heart valve disease doesn't wait for a scalpel anymore. Over the last decade, catheter-based repair and replacement technologies have quietly rewritten how cardiologists treat some of the most serious structural problems in the heart — and the market behind these devices is expanding just as fast as the science. Here's a closer look at where the structural heart devices industry stands today, who's driving it, and where it's headed through 2033.

Market Overview & Key Metrics

The global structural heart devices market is valued at roughly $18.6 billion in 2025 and is estimated to reach about $21.1 billion in 2026. From there, the market is projected to reach $51.0 billion by 2033, reflecting a compound annual growth rate (CAGR) of 13.5% between 2026 and 2033 — more than doubling in under a decade.

What's fueling this growth? A few forces stand out:

• A heavier global cardiovascular disease burden. Recent research estimates the age-standardized prevalence of cardiovascular disease at roughly 7,179 cases per 100,000 people worldwide, underscoring just how widespread valvular and structural heart conditions have become.
• Rising mortality in high-income markets. In the U.S. alone, cardiovascular disease was linked to over 931,000 deaths in a single recent year, with the age-adjusted death rate climbing by 4%. That translates to roughly 2,500+ CVD-related deaths every single day, and a new heart attack occurring somewhere in the country on average every 40 seconds.
• Government and research investment. Public agencies are actively funding better diagnostics — for example, a federal research grant awarded to the University of California, Irvine is supporting the development of a new echocardiographic imaging tool aimed at more accurately measuring mitral regurgitation severity, which helps physicians refer patients to the right intervention earlier.
• Regulatory pathways built for speed. Programs like the FDA's Breakthrough Devices designation are helping shorten the runway between innovation and patient access, even as agencies like the FDA, EMA, and PMDA maintain strict safety requirements.

Importantly, there's no real substitute for these devices. Medication can manage symptoms of valve disease, but it can't correct a structural defect — and once a valve has degenerated significantly, a device-based repair or replacement is often the only viable path forward.

Market Segmentation & Regional Share

By type, the market splits into four core categories: TAVR (Transcatheter Aortic Valve Replacement), SAVR (Surgical Aortic Valve Replacement), Mitral Repair (Annuloplasty), and LAAC (Left Atrial Appendage Closure).

• TAVR leads the pack, holding the largest revenue share at roughly 53.4% in 2024. Its dominance is being reinforced by continuous product innovation — for instance, a newly launched TAVR system in Mexico from an emerging medtech player is aimed at expanding access to minimally invasive valve therapy in markets that have historically relied on surgery.
• SAVR is far from obsolete. It's expected to see solid growth of its own, helped along by design upgrades like laser-cut leaflets and zero-pressure fixation processes that are improving the durability and handling of surgical valves.
• Mitral repair is one of the more dynamic corners of the market, with newer transcatheter chordal replacement platforms attracting fresh funding as companies chase outcomes that rival traditional surgical repair — particularly appealing for younger, higher-risk patients.

Want to go deeper into the numbers behind this market? Explore the full market segmentation and forecast data to see country-level breakdowns and detailed revenue projections through 2033.

By region, the geographic story is just as telling:

• North America dominates, commanding about 52.5% of global revenue in 2024. That lead is being reinforced by public health investment — a recent multimillion-dollar CDC grant to the American Heart Association is funding national campaigns to raise awareness of heart valve disease, particularly among historically underserved groups like women.
• Canada is the fastest-growing market within North America, even as the U.S. remains the region's largest single contributor, driven by strong clinical trial activity and rapid adoption of newer transcatheter technologies.
• Asia Pacific is the fastest-growing region globally. With close to 697 million people aged 60 and older, the region carries an enormous and growing pool of patients who are natural candidates for structural heart interventions. Countries like China, Japan, and India are each seeing accelerated device launches and distribution partnerships as healthcare infrastructure expands.
• Europe continues to post steady growth, powered by countries like Germany, the UK, and Italy, where rising cardiovascular incidence rates — in Italy's case, nearly double the global average — are pushing demand for both surgical and transcatheter options.
• Latin America and the Middle East & Africa are earlier in their growth curves but are gaining momentum through medical tourism, new cardiac care infrastructure investment, and expanding partnerships with global device makers.

Key Industry Players & Recent Milestones

A small group of established medtech giants continues to shape the direction of this market, including Boston Scientific Corporation, Medtronic, Edwards Lifesciences Corporation, Abbott Laboratories, St. Jude Medical, Biomerics, Comed BV, LivaNova PLC, JenaValve Technology, and CardioKinetix.

Recent milestones show just how fast the competitive landscape is moving:

• Medtronic secured CE mark approval for its next-generation Evolut FX+ TAVR system, which features coronary access windows roughly four times larger than earlier models — a meaningful upgrade for physicians managing patients who may need future coronary procedures.
• Edwards Lifesciences announced plans to acquire JenaValve Technology and Endotronix in a combined deal valued at around $1.2 billion, a move designed to deepen its transcatheter valve and hemodynamic monitoring capabilities.
• CardioMech AS closed a $13 million funding round to advance its transcatheter mitral repair platform toward first-in-human trials in the U.S., signaling continued investor confidence in next-gen mitral technologies.
• Pi-Cardia received FDA De Novo authorization for its Shortcut system, designed to reduce the risk of coronary obstruction during valve-in-valve TAVR procedures.
• LUMA Vision earned FDA clearance for its VERAFEYE platform, which provides real-time 360° catheter navigation for structural heart and electrophysiology procedures.
• Corcym received FDA approval for an enhanced version of its Perceval Plus sutureless surgical valve, incorporating laser-cut leaflets and a novel zero-pressure fixation process to improve long-term durability.

These moves point to a clear industry pattern: companies are racing not just to launch new devices, but to make existing ones safer, more precise, and easier to use in complex, high-risk cases — particularly as TAVR expands into younger patient populations who will need these valves to last for decades.

The Road Ahead

With a market set to triple in size by 2033, structural heart devices are becoming one of the most closely watched categories in medtech. The combination of an aging global population, rising cardiovascular disease burden, and a steady cadence of regulatory approvals suggests this growth trajectory has real staying power — not just a short-term bump.

Curious how this data applies to your specific market or region? Request a customized version of this report — free customization is available to tailor the scope to your needs.